The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Characteristically, next to the lining epithelium, there is an intense lymphocytic infiltrate. Superimposed infection may convert these lesions into abscess cavities, and rarely, give rise to cancers. Another disorder is that of thyroid dysgenesis which can result in various presentations of one or more misplaced accessory thyroid glands. These can be asymptomatic.
Examples of membrane-spanning protein phosphatases containing both active (phosphatase) and inactive (pseudophosphatase) domains linked in tandem are known, conceptually similar to the kinase and pseudokinase domain polypeptide structure of the JAK pseudokinases. A complete comparative analysis of human phosphatases and pseudophosphatases has been completed by Manning and colleagues, forming a companion piece to the ground-breaking analysis of the human kinome, which encodes the complete set of ~536 human protein kinases.
== Further reading == De Vito, D.; Weber, J.; Merbach, A. E. “Calculated Volume and Energy Profiles for Water Exchange on t2g 6 Rhodium(III) and Iridium(III) Hexaaquaions: Conclusive Evidence for an Ia Mechanism” Inorganic Chemistry, 2004, Volume 43, pages 858–863. doi:10.1021/ic035096n Zumdahl, Steven S. Chemical Principles, Fifth Edition. New York: Houghton Mifflin, 2005. 943–946, 957. OCLC 77760970 Harris, D., Bertolucci, M., Symmetry and Spectroscopy. 1989 New York, Dover Publications
Three zoos, the Paris Zoological Park (Parc zoologique de Paris, also known as the Zoo de Vincennes), at the Bois de Vincennes in the 12th arrondissement, the Cleres Zoological Park (Parc zoologique de Clères), at a medieval manor in Clères (Seine-Maritime) and the Haute Touche Zoological Park in Obterre (Indre), the largest in France, Three botanical parks, the Arboretum de Chèvreloup in Rocquencourt next to the Château de Versailles, the Jardin botanique exotique de Menton and the Jardin alpin de La Jaÿsinia in Samoëns, Two museums, the Musée de l'abri Pataud in Les Eyzies-de-Tayac and the Harmas de Fabre in Sérignan-du-Comtat, Four scientific sites, the Institut de Paléontologie humaine in Paris, the Centre d'Écologie générale de Brunoy, the Station de Biologie marine et Marinarium de Concarneau and the CRESCO (Centre de Recherche et d'Enseignement sur les Systèmes Côtiers) in Dinard.
Sources: en.wikipedia.org
The structure of prolactin is similar to that of growth hormone and placental lactogen. The molecule is folded due to the activity of three disulfide bonds. Significant heterogeneity of the molecule has been described, thus bioassays and immunoassays can give different results due to differing glycosylation, phosphorylation and sulfation, as well as degradation. The non-glycosylated form of prolactin is the dominant form that is secreted by the pituitary gland. The three different sizes of prolactin are:
Without this reactivity reserve, a reactor shutdown would preclude its restart for several tens of hours until 135I/135Xe sufficiently decays, especially shortly before replacement of spent fuel (with high burnup and accumulated nuclear poisons) with fresh fuel. Fluid fuel reactors cannot develop xenon inhomogeneity because the fuel is free to mix. Also, the Molten Salt Reactor Experiment demonstrated that spraying the liquid fuel as droplets through a gas space during recirculation can allow xenon and krypton to leave the fuel salts.
== Medical uses == Lobeglitazone is used to assist regulation of blood glucose level of diabetes mellitus type 2 patients. It can be used alone or in combination with metformin. Lobeglitazone was approved by the Ministry of Food and Drug Safety (Korea) in 2013, and the postmarketing surveillance is on progress until 2019.
Sources: en.wikipedia.org
Peptide hormones GHRH (somatocrinin) through binding to the growth hormone-releasing hormone receptor (GHRHR) Ghrelin through binding to growth hormone secretagogue receptors (GHSR) Sex hormones Increased androgen secretion during puberty (in males from testes and in females from adrenal cortex) Testosterone and DHEA Estrogen Clonidine, moxonidine and L-DOPA by stimulating GHRH release α4β2 nicotinic agonists, including nicotine, which also act synergistically with clonidine or moxonidine. Hypoglycemia, arginine, pramipexole, lysine, tryptophan, γ-Aminobutyric acid and propranolol by inhibiting somatostatin release Deep sleep Glucagon Sodium oxybate or γ-Hydroxybutyric acid Niacin as nicotinic acid (vitamin B3) Fasting Insulin Vigorous exercise Inhibitors of GH secretion include:
=== Drug War Capitalism === In 2014, journalist Dawn Paley wrote Drug War Capitalism, a book that highlights how the war on drugs functions as a tool for the US to leverage control and power over Latin America. As she points out, the US has increasingly been able to militarise parts of Latin America as a pretext for fighting the war on drugs, when in reality this militarisation serves to oppress local communities and open new lands to extract the region's vast mineral and oil wealth. Increased paramilitary, private military, and national sector (police and military force) violence against local communities coincides with economically significant regions in countries like Colombia, such as areas either with vast mineral wealth or areas where oil pipelines run through. Paley points to major joint security initiatives involving the US and Latin American countries, such as Plan Colombia with Colombia, and the Mérida Initiative with Mexico, which both resulted in increased extraction of natural resources, increased militarisation, and a weakened justice system. This occurred whilst the plans' prohibitiotary aims, to combat drug trafficking levels and drug cartels, completely failed.
Non-radiogenic Pb is negligible compared to radiogenic Pb. No modification of U/Th/Pb has occurred except radioactivity. The first assumption tends to be true since monazite is very unlikely to incorporate Pb during its growth. The non-radiogenic Pb content in many laboratory tests was found to be very low, nearly always less than 1 ppm. The most common error arising from this assumption is contamination with lead during sample preparation. The second assumption is usually justified by the concordant behavior of the mineral observed in tests. That means the system is either reset totally or unaffected totally by geological processes, there is no partial resetting of the system. Minor errors may arise due to negligible disturbance during mass transfer. The theory is that monazite has high contents of Th (generally 3–15% and up to 25% of its weight) and U (generally hundreds of ppm and up to 5% in concentration). Thus, Pb accumulates at a high rate by radioactive processes. In less than hundreds of years, it reaches a level high enough to be measured accurately by an electron microprobe.
In the Republic of the Congo, also known as Congo-Léopoldville, newly independent from Belgium since June 1960, the Congo Crisis erupted on 5 July leading to the secession of the regions Katanga and South Kasai. CIA-backed President Joseph Kasa-Vubu ordered the dismissal of the democratically elected Prime Minister Patrice Lumumba and the Lumumba cabinet in September over massacres by the armed forces during the invasion of South Kasai and for involving Soviets in the country. Later the CIA-backed Colonel Mobutu Sese Seko quickly mobilized his forces to seize power through a military coup d'état, and worked with Western intelligence agencies to imprison Lumumba and hand him over to Katangan authorities who executed him by firing squad. In British Guiana, the leftist People's Progressive Party (PPP) candidate Cheddi Jagan won the position of chief minister in a colonially administered election in 1953 but was quickly forced to resign from power after Britain's suspension of the still-dependent nation's constitution. Embarrassed by the landslide electoral victory of Jagan's allegedly Marxist party, the British imprisoned the PPP's leadership and maneuvered the organization into a divisive rupture in 1955. Jagan again won the colonial elections in 1957 and 1961, despite Britain's shift to a reconsideration of its view of the left-wing Jagan as a Soviet-style communist at this time. The United States pressured the British to withhold Guyana's independence until an alternative to Jagan could be identified, supported, and brought into office.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。